George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
Todays RNS mentioned one government and in the Shares presentation I think he mentioned the U.K., Germany and the USA. Plus, post the comments he made in the FT a couple of months ago as regards the difficulty of getting through to the right person at the NHS, I would be surprised if it wasn’t the NHS
I have read the Jefferies and Berenberg reports. Both seem ignorant of the important point, made in both of the CEO webinars, that FDA approval allows AGL to sell the Parsortix system as a product, not just a service. This should greatly enhance the revenue and profit stream once reimbursement codes are assigned. Which hospital wouldn’t want this product given its lower cost and efficacy ? Market size is hard to estimate, I agree, but very little mention is made of this in the broker reports. Is it just me, or have other posters noticed this same omission ?
‘Nuff said
I re read the RNS. I think it referred to sales made YTD, which was January and February, +150% YOY.
Pretty hard to bankrupt the company when
There is no debt
There is cash
The business is profitable and cashflow positive
Sales are growing.
If it’s good enough for Veloso at $50/ton why not for everyone ? I thought Veloso were a major player in Brazil ?
Actually they did buy at 3p or so a few months ago. They are sitting on so much market sensitive information as regards financing right now (Otakikpo 2, OPL310) that I don’t think their NOMAD would allow them to buy
Stock at an all time low. Yet the near term outlook as regards profitability would seem to be better than ever. Otakikpo 2 and OPL 310 financing are, per the company at least, around the corner.
OPL310 back costs are over $100m plus 50% and with compound interest so likely closer to $200m. Company expects to drill this year if financing sorted.
Bed and breakfast ? With a net sale of 1m shares ?
The thing is that it is not up to the BoD, it is up to the shareholders. People are, rightly, worried that their fellow shareholders might take a cheeky low ball bid now rather than wait and capture (more) value later
Reading the Hamman report again... Lekoil’s stake in OPL310 comes with $200m of back costs. That’s a good starting point in the event it gets sold
Good for you Y Alam, so pleased it has worked out for you/us. I started at 20p and averaged down. I won’t sell a share until I see 20p
Saw the interview. At the end PB says, ‘It’s gonna be a big year, yeah’. And so it has been. All of this worrying about a cash raise (which may or may not happen, I think not) is a distraction. They key point is that TXP is investing capital at very high IRRs and has many more opportunities to do that. That speaks to a much higher stock price in a year.
Nudge nudge, wink, wink